GRI Bio (GRI) vs PharmaCyte Biotech (PMCB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
PharmaCyte Biotech is the larger company by market cap ($4.3 million vs $3.7 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GRI | PMCB |
|---|---|---|
| Share price | $1.68 | $0.3974 |
| Market cap | $3.67M | $4.27M |
| 1-day change | -9.19% | -2.02% |
| EPS (TTM) | $-14.71 | $-2.31 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $64.12 | $1.51 |
| 52-week low | $1.36 | $0.3339 |
| Distance from 52-week high | -97.38% | -73.68% |
| Analyst consensus | none | — |
| Avg. price target upside | +1001.19% | — |
| Average volume | 328.06K | 205.72K |
| Shares outstanding | 2.19M | 10.74M |
| Employees | 3 | 2 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About GRI Bio
GRI stock →GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 3 employees
About PharmaCyte Biotech
PMCB stock →PharmaCyte Biotech, Inc., a biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States. The company's cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 2 employees
GRI vs PMCB FAQ
Which is bigger, GRI Bio or PharmaCyte Biotech?
PharmaCyte Biotech (PMCB) is larger, with a market capitalization of $4.27M compared with $3.67M for GRI Bio (GRI).
Are GRI Bio and PharmaCyte Biotech in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for GRI Bio and Biotechnology: Biological Products (No Diagnostic Substances) for PharmaCyte Biotech.